Streetbeat News

Revenues

DAVE

Over the past three months, Dave Inc (NASDAQ:DAVE) received diverse analyst ratings, ranging from bullish to bearish, with a recent shift towards a somewhat bullish outlook. The average 12-month price target for Dave has been raised to $58.75, indicating a positive sentiment shift. Analysts from JMP Securities and Barrington Research have adjusted their ratings and price targets, reflecting an optimistic view on Dave's financial performance, which includes a notable revenue growth rate of 22.53%, an exceptional net margin of 0.24%, and strong ROE and ROA figures. However, Dave's high debt-to-equity ratio of 2.08 poses a challenge.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 7:00 pm

DK

Delek US Holdings (NYSE:DK) has been analyzed by 7 analysts, showing a consensus towards an indifferent stance with 5 neutral ratings, 2 somewhat bearish, and no bullish opinions. The average 12-month price target for DK has been raised to $28.57, indicating a 6.37% increase from the previous target. Analyst actions include both upgrades and downgrades, reflecting varied expectations for the company's performance. Despite the financial challenges such as a revenue decline of -9.6%, a net margin of -4.07%, and a high debt-to-equity ratio of 3.27, analysts have adjusted their price targets based on recent developments.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 7:00 pm

NYT

The New York Times (NYSE:NYT) reported a net increase of 210,000 digital-only subscribers in Q1, reaching 9.91 million, with overall subscribers at 10.55 million. Sales rose 5.9% to $594 million, beating consensus. Digital ad revenues increased 2.9%, while total ad revenues fell 2.4%. The Athletic's subscribers grew 52.6% to 4.99 million, with revenues up 33%. Adjusted EPS was $0.31, up 63%. Q2 guidance anticipates subscription revenues to grow 6%-8% and digital ad revenues to increase in the high single digits. NYT shares rose 3.69% to $47.96.

Portfolio Pulse from Vandana Singh

May 08, 2024 | 6:56 pm

CRCT

DV

EMR

INOD

INSP

REBN

TMCI

U.S. stocks showed mixed performance with the Dow Jones gaining over 150 points, while NASDAQ fell slightly. Emerson Electric Co. reported better-than-expected Q2 results, revising its FY24 outlook upwards. Other notable movements included significant gains for Reborn Coffee, Inc., Cricut, Inc., and Innodata Inc., and sharp declines for Treace Medical Concepts, Inc., DoubleVerify Holdings, Inc., and Inspire Medical Systems, Inc. Commodities and global market trends were also highlighted.

Portfolio Pulse from Avi Kapoor

May 08, 2024 | 6:41 pm

KVUE

Analyst ratings for Kenvue (NYSE:KVUE) show varied perspectives, with recent evaluations ranging from bullish to bearish. The average 12-month price target is now $21.57, down from $23.20. Analyst actions include adjustments to ratings and price targets, reflecting changes in market conditions and company performance. Kenvue, a spin-off from Johnson & Johnson's consumer segment, is the world's largest pure-play consumer health company, facing a slight revenue decline but maintaining strong profitability indicators.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 6:01 pm

HLMN

Hillman Solns (NASDAQ:HLMN) received mixed analyst ratings with a shift towards a more bullish outlook in the last quarter. Analysts from Baird, Stifel, Barclays, and Canaccord Genuity adjusted their price targets upwards, reflecting a positive sentiment shift. The average 12-month price target is now $12.6, up from $11.40. Despite this, Hillman Solns faces financial challenges, including a revenue decline of -0.81% in the last 3 months of 2023, a net margin of -2.89%, and a high debt-to-equity ratio of 0.72.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 6:01 pm

PAGP

Plains GP Holdings (NASDAQ:PAGP) has been analyzed by 8 analysts, showing a mix of ratings from bullish to bearish. Recent updates include raised price targets and ratings, with an average 12-month price target of $19.69, marking an 11.62% increase from the previous $17.64. The company faces challenges such as a -1.96% revenue decline, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio, indicating potential financial strain.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 6:00 pm

IONS

Ionis Pharmaceuticals (NASDAQ:IONS) received mixed ratings from 8 analysts, with a shift towards more bullish perspectives in the last 30 days. The average 12-month price target is now $67.12, down from $69.40. Analysts' actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to the company's performance and market conditions. Ionis, known for its antisense technology and drugs like Spinraza and Qalsody, shows a strong revenue growth rate of 113.65% but faces challenges in market capitalization, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 6:00 pm

REBN

TMCI

UPST

Upstart Holdings, Inc. (UPST) shares fell by 10.3% after reporting Q1 financial results and issuing Q2 revenue guidance below estimates. Other stocks showed significant movement, with Reborn Coffee, Inc. (REBN) leading gainers with a 132.9% jump after announcing a market expansion into China. On the losing end, Treace Medical Concepts, Inc. (TMCI) dropped 60.8% after issuing FY24 revenue guidance below estimates.

Portfolio Pulse from Avi Kapoor

May 08, 2024 | 5:38 pm

PRPL

Purple Innovation (NASDAQ:PRPL) has been analyzed by 6 analysts, showing a shift towards more positive ratings with an average 12-month price target of $2.25, up 45.16% from the previous target. The company's financials indicate a positive revenue trend and exceptional net margin, despite a market capitalization below industry averages and lower ROE and ROA. Analysts' ratings range from 'Outperform' to 'Neutral', reflecting varied expectations for the company's stock performance.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 5:01 pm